Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin

American Journal of Gastroenterology

Volumn 110, Issue 8, 2015, Pages 1179-1185

  Shiffman, Mitchell L ^a   James, Amy M ^a   Long, April G ^a   Alexander, Philip C ^a  

^a Bon Secours Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; FUSED HETEROCYCLIC RINGS; INTERFERON; SULFONAMIDE; URIDINE PHOSPHATE; VIRUS RNA;

ADULT; AFRICAN AMERICAN; AGED; ANTIVIRAL THERAPY; ARTICLE; BLEEDING; CAUCASIAN; CHILD PUGH SCORE; CHRONIC HEPATITIS C; CHRONOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; HYPERBILIRUBINEMIA; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SEPSIS; THORAX PAIN; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; VARICEAL BLEEDING; VARICOSIS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; COMPLICATION; CONTRAINDICATIONS; DRUG COMBINATION; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER TUMOR; PATHOPHYSIOLOGY; PROCEDURES; TIME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; HYPERBILIRUBINEMIA; INTENTION TO TREAT ANALYSIS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SEPSIS; SULFONAMIDES; TIME FACTORS; URIDINE MONOPHOSPHATE;

EID: 84939253435     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.218     Document Type: Article

References (38)

1. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C withlow-dose peginterferon. N Engl J Med 2008; 359: 2429-41
2. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 200 Ann Intern Med 2012; 156: 271-8
3. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008; 12: 733-46
4. Fox RK. When to consider liver transplant during the management of chronic liver disease. Med Clin North Am 2014; 98: 153-68
5. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C witha low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62
6. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis in patients withadvanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-97
7. Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients withHCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-42
8. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-28
9. Manns M, Marcellin P, Poordad F, et al. Simeprevir withpegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients withchronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26
10. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87
11. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, withor without ribavirin, to treat chronic infection withhepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatmentnaive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65
12. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88
13. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98
14. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93
15. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir withor without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92
16. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir withribavirin for hepatitis C withcirrhosis. N Engl J Med 2014; 370: 1973-82
17. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV withABT-450/r-ombitasvir and dasabuvir withribavirin. N Engl J Med 2014; 370: 1594-603
18. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV withABT-450/r-ombitasvir and dasabuvir withribavirin. N Engl J Med 2014; 370: 1604-14
19. Recommendations for testing, managing and treating hepatitis C American Association for the Study of Liver Diseases and Infectious Disease Society of American http:/www.hcvguidelines.org/full-report-viewAASLD guidelines , Accessed on 1 March 2014
20. Simeprevir package insert. Revised November 2014
21. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98
22. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93
23. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir withribavirin for hepatitis C withcirrhosis. N Engl J Med 2014; 370: 1973-82
24. Bourliere M, Sulkowski MS, Omata M, et al. An integrated safety and efficacy analysis of 500 patients withcompensated cirrhosis treated withlepisasvir/sofosbuvir withor without ribavirin. Hepatology 2014; 60: 239A
25. Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir withribavirin for the treatment of HCV in patients withpost-transplant recurrence: Preliminary results of a prospective, multicenter study. Hepatology 2014; 60: 209A
26. Manns M, Forns X, Samuel D, et al. Ledipasvir/sofosbuvir withribavirin is safe and efficacious in decompensated and post-liver transplant patients withHCV infection: preliminary results of the prospective SOLAR 2 trial. J Hepatol 2015; 62: S187-8
27. Jensen DM, O'Leary JG, Pockros PJ, et al. safety and Efficay of sofosbuvircontaining regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Hepatology 2014; 60 ( suppl ): 219A
28. Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60: 220A
29. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients withchronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84
30. Morgan TR, Ghany MG, Kim HY, et al. HALT-C Trial Group. Outcome of sustained virological responders withhistologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44
31. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients withhepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16
32. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients withchronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93
33. Stine JG, Intagliata N, Shah NL, et al. Hepatic Decompensation likely attributable to simeprevir in patients withadvanced cirrhosis. Dig Dis Sci 2014; 60: 1031-5
34. Lok AS, SeEffLB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48
35. Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment withsofosbuvircontaining regimens for hepatitis C virus. Hepatology 2015; 61: 41-5
36. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients withchronic hepatitis C treated withpeginterferon alfa-2a and ribavirin. Gastroenterol 2010; 139: 1593-601
37. Manns MP, Pockros PJ, Norkrans G, et al. Long-term clearance of hepatitis C virus following interferon a -2b or peginterferon a -2b, alone or in combination withribavirin. J Viral Hepat 2013; 20: 524-9
38. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77